Resposta virológica sustentada às drogas de ação direta de segunda geração para hepatite C

Adriana Parise Compri; Vanessa Cristina Martins Silva; Marcilio Figueiredo Lemos; Isabel Takano Oba; Regina Célia Moreira

doi:10.57148/bepa.2020.v.17.33949

Authors

Adriana Parise Compri Laboratório de Hepatites Virais, Centro de Virologia, Instituto Adolfo Lutz, São Paulo, SP
Vanessa Cristina Martins Silva Laboratório de Hepatites Virais, Centro de Virologia, Instituto Adolfo Lutz, São Paulo, SP
Marcilio Figueiredo Lemos Laboratório de Hepatites Virais, Centro de Virologia, Instituto Adolfo Lutz, São Paulo, SP
Isabel Takano Oba Laboratório de Hepatites Virais, Centro de Virologia, Instituto Adolfo Lutz, São Paulo, SP
Regina Célia Moreira Laboratório de Hepatites Virais, Centro de Virologia, Instituto Adolfo Lutz, São Paulo, SP

DOI:

https://doi.org/10.57148/bepa.2020.v.17.33949

Keywords:

Chronic Hepatitis C, Observational study, Treatment, Genotype, Sustained virologic response

Abstract

Background: Recently, the management of patients chronically infected with the hepatitis C virus has progressed, including second generation direct-acting antivirals (DAA) that have potential to clear infection in most patients, especially genotype 1-infected patients. Objectives: Evaluate the sustained virologic response (SVR) of Hepatitis C treatment with second-generation DAAs made available by the Ministry of Health in follow-up patients of a São Paulo health service. Methods: This was a retrospective observational study, based on secondary data obtained from GAL and MEDEX systems. Briefly, 615 convenience samples were analyzed of patients who underwent second-generation DAAs treatment from June 2016 to April 2018. Demographic and clinical data were also analyzed. Results: SVR was observed in 600 treated patients (97.6%). Further, 98.4% and 94.7% of genotype 1 and genotype 3 patients, respectively, responded to treatment (P = 0.02). Among patients who did not respond to treatment, 93.3% were male, naive treatment and were treated for 12 weeks, except one genotype 1, HIV-coinfected patient who received treatment for 24 weeks. Conclusions: A high rate of SVR was found for Hepatitis C treatment with second-generation DAAs. SVR was significantly reduced in male and genotype 3-infected patients, although it still exceeded 90%. Further, HIV coinfection showed no association with reduced SVR rates (p=0.98).

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

1. World Health Organization (WHO). Global hepatitis report. 2017. Available at: http://www.who.int/iris/handle/10665/255016. Acessed on: 20.jul.2019.
2. Amaku M, Burattini MN, Coutinho FAB, Lopez LF, Mesquita F, Naveira MC, et al. Estimating the size of the HCV infection prevalence: a modeling
approach using the incidence of cases reported to an official notification system. Bull Math Biol. 2016;78(5):970-90.
3. Chew KW, Allen SA, Taylor LE, Rich JD, Feller E. Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis C. J Clin Gastroenterol. 2009;43(7):686-91.
4. Iacomi F, Iannicelli G, Franceschini A, Migliorisi P, Rosati S, Piselli P, et al. HCV infected prisoners: Should they be still considered a difficult to treat
population? BMC Infect Dis. 2013;13:374.
5. Pawlotsky JM. New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development. Semin Liver Dis. 2014;34(1):22-9.
6. Cheinquer H, Sette H Jr, Wolff FH, de Araujo A, Coelho-Borges S, Soares SRP, et al. Treatment of Chronic HCV Infection with the New Direct Acting Antivirals (DAA): First Report of a Real World Experience in Southern Brazil. Ann Hepatol. 2017;16(5):727-33.
7. European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55(2):245-64.
8. Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, et al. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol. 2011;8(4):212-23.
9. European Association for the Study of the Liver (EASL). EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63(1):199-236.
10. Zhang J, Nguyen D, Hu KQ. Chronic Hepatitis C Virus Infection: A Review of Current Direct-Acting Antiviral Treatment Strategies. N Am J Med Sci. 2016;9(2): 47-54.
11. Kwo P, Gitlin N, Nahass R, Bernstein D, Etzkom K, Rojter S, et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-
infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatol. 2016;64(2): 370-80.
12. Höner Zu Siederdissen C, Buggisch P, Böker K, Schott E, Klinker H, Pathil A, et al. Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in areal-world setting. United European Gastroenterol J. 2018;6(2):213-24.
13. Lanini S, Scognamiglio P, Mecozzi A, Lombardozzi L, Vullo V, Angelico M, et al. Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study. BMC Infect Dis. 2018;18(1):223.
14. Ministério da Saúde (MS). Secretaria de Vigilância em Saúde. Departamento de DST, Aids e Hepatites Virais. Protocolo Clínico e Diretrizes Terapêuticas para Hepatite C e Coinfecções/ Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de DST, Aids e Hepatites Virais. Brasília: MS; 2015. 101p. Available at http://bvsms.saude.gov.br/bvs/publicacoes/protocolo_clinico_diretrizes_hepatite_co_coinfeccoes. pdf. Acessed on: 14.set.2019.
15. Ferreira VL, Assis Jarek NA, Tonin FS, Borba HH, Wiens A, Pontarolo R. Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis. J Clin Pharm Ther. 2016;41(5):478-85.
16. Ferreira VL, Assis Jarek NA, Tonin FS, Borba HH, Wiens A, Muzzillo DA, et al. Ledipasvir/sofosbuvir with or without ribavirin for the treatment
of chronic hepatitis C genotype 1: a pairwise meta-analysis. J Gastroenterol Hepatol. 2017;32(4):749-55.
17. Ferreira VL, Borba HHL, Wiens A, Pedroso MLA, Radunz VFC, Ivantes CAP, et al. Effectiveness and tolerability of directacting antivirals for chronic hepatites C patients in a Southern state of Brazil. Braz J Infect Dis. 2018;22(3):186-92.
18. Martins RMB, Teles SA, Freitas NR, Motta-Castro AR, Souto FJ, Mussi A, et al. Distribution of hepatitis C virus genotypes among blood donors from
mid-west region of Brazil. Rev Inst Med Trop Sao Paulo. 2006;48(1):53-5.
19. Lopes CLR, Teles SA, Espirito-Santo MP, Lampe E, Rodrigues FP, Motta-Castro AR, et al. Prevalence, risk factors and genotypes of hepatitis C virus infection among drug users, Central-Western Brazil. Rev. Saude Publica. 2009;43(1):43-50.
20. Carvalho AC, Junior JLP, Silva MFO, Neto SGS. Perfil genotípico da hepatite C em um laboratório público do estado do Piauí. R. Interd. 2014;7(3):55-60.
21. Naveira MCM, Almeida EC, Cattapan E, Fernandes N, Gomes JN, Graner B, et al. New antivirals for hepatitis Cin Brazil: preliminary effectiveness
analysis with current national databases. Ann Hepatol. 2016;15(6):997.
22. Medeiros T, Salviato CM, do Rosario NF, Saraiva GDN, Esberard EBC, Almeida JR, et al. Adverse effects of direct acting antiviral-based regimens in chronic hepatitis C patients: a Brazilian experience. Int J Clin Pharm. 2017;39(6):1304-11.
23. Ministério da Saúde (MS). Secretaria de Vigilância em Saúde. Departamento de Vigilância, Prevenção e Controle das Infecções Sexualmente Transmissíveis, do HIV/Aids e das Hepatites Virais. Protocolo Clínico e Diretrizes Terapêuticas para Hepatite C e Coinfecções / Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de Vigilância, Prevenção e Controle das Infecções Sexualmente Transmissíveis, do HIV/Aids e das
Hepatites Virais. Brasília: MS; 2019. 68 p. Available at http://www.aids.gov.br/pt-br/pub/2017/protocolo-clinico-e-diretrizesterapeuticas-para.hepatite-c-e-coinfeccoes. pdf. Acessed on: 21.ago.2019.
24. Ingiliz P, Christensen S, Kimhofer T, Hueppe D, Lutz T, Schewe K, et al. Sofosbuvir and ledipasvir for 8 weeks for the treatment of chronic hepatitis C virus (HCV) infection in HCV-monoinfected and HIV-HCV–coinfected individuals: Results from the German Hepatitis C Cohort (GECCO-01). Clin Infect
Dis. 2016;63(10):1320-4.